Fintel reports that on November 15, 2024, Redburn Atlantic upgraded their outlook for Autolus Therapeutics plc - Depositary Receipt () (NasdaqGS:AUTL) from Neutral to Buy. Analyst Price Forecast ...

Analyst Sean Lee CFA from H.C. Wainwright maintained a Buy rating on Plus Therapeutics (PSTV – Research Report) and keeping the price ...

Piper Sandler analyst Biren Amin lowered the firm’s price target on Allogene Therapeutics (ALLO) to $9 from $11 and keeps an Overweight ...

Nektar continues to make progress with rezpegaldesleukin, with results from phase 2 atopic dermatitis study expected in H1'25 ...

We recently published a list of 10 Best Multibagger Stocks To Buy Heading into 2025. In this article, we are going to take a ...

PTC Therapeutics' gene therapy is already approved in the European ... while European stocks rose on hopes of a better growth ...

After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...

CEO Roberto Iacone admitted in an interview that the market remains tough, even for a biotech in the red-hot ADC world. But ...

Digital health company Better Therapeutics has submitted its lead prescription digital therapeutic (DTx) BT-001 to the FDA, seeking approval for use by adults with type 2 diabetes (T2D).

The merger comes just a few days after the assets of another digital health pioneer – Better Therapeutics – were sold to Click Therapeutics after it shut down operations, three years after its ...